<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJS</journal-id>
<journal-id journal-id-type="hwp">spijs</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Surg Pathol</journal-id>
<journal-title>International Journal of Surgical Pathology</journal-title>
<issn pub-type="ppub">1066-8969</issn>
<issn pub-type="epub">1940-2465</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1066896911434548</article-id>
<article-id pub-id-type="publisher-id">10.1177_1066896911434548</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Sporadic Hemangioblastoma of the Kidney in a 29-Year-Old Man</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Chung-Chieh</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911434548">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Shuo-Meng</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911434548">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Liau</surname><given-names>Jau-Yu</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911434548">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1066896911434548"><label>1</label>National Taiwan University Hospital, Taipei, Taiwan</aff>
<author-notes>
<corresp id="corresp1-1066896911434548">Jau-Yu Liau, Department of Pathology, National Taiwan University Hospital, No. 7, Chung Shan S Rd, Taipei 100, Taiwan Email: <email>019188@ntuh.gov.tw</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>10</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<issue>5</issue>
<fpage>519</fpage>
<lpage>522</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Hemangioblastoma of the kidney is a rare, newly recognized tumor with morphological features similar to its cerebellar counterpart. There have been only 4 cases reported in the literature in English, all of them occurring in middle-aged to elderly patients. Here, we report a case of renal hemangioblastoma in a young adult without clinical evidence of von Hippel-Lindau disease. The tumor was composed of polygonal cells with mildly eosinophilic to clear cytoplasm and a rich vascular network. Immunohistochemical staining revealed a typical profile (positivity for α-inhibin, neuron-specific enolase and S100; negative results for epithelial membrane antigen, HMB-45, and Melan-A), which confirmed the diagnosis. Despite the similarity to renal-cell carcinoma in morphology, hemangioblastoma of the kidney is clinically indolent. Correct recognition of this pathological entity is important to avoid overdiagnosis and unnecessary clinical treatment.</p>
</abstract>
<kwd-group>
<kwd>hemangioblastoma</kwd>
<kwd>kidney</kwd>
<kwd>renal-cell carcinoma</kwd>
<kwd>von Hippel-Lindau disease</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1066896911434548" sec-type="intro">
<title>Introduction</title>
<p>Hemangioblastoma, also referred to as capillary hemangioblastoma, is an uncommon neoplasm composed of lipid-containing stromal cells and a rich vascular network. It typically occurs in the central nervous system (CNS), mostly in the cerebellum, and is categorized as a WHO grade I tumor with good clinical outcome.<sup><xref ref-type="bibr" rid="bibr1-1066896911434548">1</xref></sup> Known as a hallmark of von Hippel-Lindau (VHL) disease,<sup><xref ref-type="bibr" rid="bibr2-1066896911434548">2</xref></sup> most cases of hemangioblastoma are sporadic.<sup><xref ref-type="bibr" rid="bibr1-1066896911434548">1</xref></sup> Cases of hemangioblastoma outside the CNS are exceptional, and those without association with VHL disease are even rarer. Only a few sporadic cases have been reported, and their sites of involvement include peripheral nerve, bone, soft tissue, retroperitoneum, skin, and kidney.<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref></sup> Among them, the renal cases mainly occurred in middle-aged adults, with age ranging from 55 to 71 years.<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref><xref ref-type="bibr" rid="bibr4-1066896911434548"/>-<xref ref-type="bibr" rid="bibr5-1066896911434548">5</xref></sup> Here, we report a sporadic case of primary renal hemangioblastoma in a young man without clinical evidence of VHL disease.</p>
</sec>
<sec id="section2-1066896911434548" sec-type="cases">
<title>Case Report</title>
<p>The patient was a 29-year-old man without documented systemic disease. In a hospital visit for evaluation of abnormal liver function, abdominal sonography revealed a tumor mass in his right kidney accidentally. A computer tomography scan demonstrated a 3.1-cm ovoid mass at the lower portion of the right kidney with heterogeneous density. Reviewing the history, the patient denied hematuria, weight loss, change in appetite, or neurological symptoms and signs. In addition, there was no family history of renal or brain tumor. Under the suspicion of renal cell carcinoma (RCC), he underwent a right radical nephrectomy. The postoperative course was smooth, and there was no evidence of tumor recurrence 20 months after the surgery. Follow-up magnetic resonance imaging for the brain did not reveal any tumor, either.</p>
</sec>
<sec id="section3-1066896911434548">
<title>Pathological Findings</title>
<p>The renal specimen measured 11.0 × 4.5 × 4.0 cm<sup>3</sup> in size and weighed 158.0 g. There was a well-defined, red to brown, soft tumor measuring 2.7 × 2.5 × 2.5 cm<sup>3</sup> in size in the subcapsular renal parenchyma. Extrarenal extension or tumor thrombus was not seen grossly. There was no evidence of invasion into the renal pelvis or the ureter, either.</p>
<p>Microscopically, the renal tumor was partially encapsulated (<xref ref-type="fig" rid="fig1-1066896911434548">Figure 1A</xref>) and consisted of polygonal to oval cells arranged in sheets with a rich vascular network (<xref ref-type="fig" rid="fig1-1066896911434548">Figure 1B</xref>). Occasionally, arrangement of tumor cells around the vascular channels (so-called pericytomatous pattern) could be found (<xref ref-type="fig" rid="fig1-1066896911434548">Figure 1B</xref>). The tumor cells were slightly variable in size and shape, and their cytoplasm was mildly eosinophilic to clear with small lipid vacuoles. Their nuclei were round to oval without hyperchromasia, conspicuous nucleoli, or mitotic figures (<xref ref-type="fig" rid="fig1-1066896911434548">Figure 1C</xref>). The arborizing blood vessels were mainly small and thin walled, but ectatic staghorn-shaped vascular channels were also present. Extensive fresh hemorrhage was found in the tumor, and there were also areas of myxoid change and aggregation of hemosiderin-laden macrophages. Tumor necrosis and local invasion were absent.</p>
<fig id="fig1-1066896911434548" position="float">
<label>Figure 1.</label>
<caption>
<p>Histological features. A. The tumor (upper part) has a well-defined border against adjacent renal tissue (lower part). A fibrous capsule is partially present between them, and fresh hemorrhage is prominent in the tumor part (hematoxylin-eosin, ×40). B. The tumor is composed of polygonal to oval cells with a rich vascular network. A pericytomatous growth pattern is present around the ectatic vascular channels (hematoxylin-eosin, ×200). C. The tumor cells are bland looking with lipid vacuoles (hematoxylin-eosin, ×400). D-F. The tumor cells show positive immunohistochemical reactivity to α-inhibin (D, ×200), neuron-specific enolase (E, ×200), and S100 protein (F, ×200).</p>
</caption>
<graphic xlink:href="10.1177_1066896911434548-fig1.tif"/>
</fig>
<p>Immunohistochemical (IHC) stains were carried out using a Ventana Benchmark XT automated slide stainer (Ventana Medical Systems, Tuscon, AZ) with the Ventana iVIEW DAB detection kit. The details of the antibodies are summarized in <xref ref-type="table" rid="table1-1066896911434548">Table 1</xref>. The tumor cells were diffusely and strongly positive for vimentin. A large proportion of them were also strongly positive for α-inhibin (<xref ref-type="fig" rid="fig1-1066896911434548">Figure 1D</xref>), neuron-specific enolase (<xref ref-type="fig" rid="fig1-1066896911434548">Figure 1E</xref>), and S100 protein (<xref ref-type="fig" rid="fig1-1066896911434548">Figure 1F</xref>). The tumor cells were faintly stained against cytokeratin (AE1/AE3), and the results were regarded as negative. They were also negative for epithelial membrane antigen, CD10, CD56, HMB-45, Melan-A, and smooth muscle actin. CD34 stain highlighted the vascular network but not the tumor cells per se. <italic>VHL</italic> gene analysis using polymerase chain reaction and sequencing revealed no mutation in any of the 3 exons from the paraffin-embedded tissue sample.</p>
<table-wrap id="table1-1066896911434548" position="float">
<label>Table 1.</label>
<caption><p>Primary Antibodies Used for Immunohistochemistry</p></caption>
<graphic alternate-form-of="table1-1066896911434548" xlink:href="10.1177_1066896911434548-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Primary Antibody</th>
<th align="center">Clone</th>
<th align="center">Source</th>
<th align="center">Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokeratin (AE1 and AE3)</td>
<td>4C</td>
<td>BioGenex</td>
<td>1:100</td>
</tr>
<tr>
<td>Epithelial membrane antigen</td>
<td>E29</td>
<td>Dako</td>
<td>1:100</td>
</tr>
<tr>
<td>Vimentin</td>
<td>V9</td>
<td>Dako</td>
<td>1:50</td>
</tr>
<tr>
<td>S100</td>
<td>Polyclonal</td>
<td>BioGenex</td>
<td>1:300</td>
</tr>
<tr>
<td>HMB-45</td>
<td>HMB-45</td>
<td>Dako</td>
<td>1:40</td>
</tr>
<tr>
<td>Melan-A</td>
<td>A103</td>
<td>Dako</td>
<td>1:25</td>
</tr>
<tr>
<td>Smooth muscle actin</td>
<td>1A4</td>
<td>Dako</td>
<td>1:50</td>
</tr>
<tr>
<td>CD10</td>
<td>J.149</td>
<td>Novocastra</td>
<td>1:50</td>
</tr>
<tr>
<td>CD34</td>
<td>QBEnd/10</td>
<td>BioGenex</td>
<td>1:20</td>
</tr>
<tr>
<td>CD56</td>
<td>1B6</td>
<td>Novocastra</td>
<td>1:100</td>
</tr>
<tr>
<td>Neuron-specific enolase</td>
<td>BBS/NC/VI-H14</td>
<td>Dako</td>
<td>1:200</td>
</tr>
<tr>
<td>α-Inhibin</td>
<td>mac951s</td>
<td>Bio-Innova</td>
<td>1:80</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section4-1066896911434548" sec-type="discussion">
<title>Discussion</title>
<p>Hemangioblastoma is an uncommon neoplasm mainly occurring in the CNS.<sup><xref ref-type="bibr" rid="bibr1-1066896911434548">1</xref></sup> Extraneural cases are exceptional, and they are usually found in patients with known VHL disease.<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref></sup> To date, there have been only 4 cases of sporadic hemangioblastomas of the kidney reported in the literature in English.<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref><xref ref-type="bibr" rid="bibr4-1066896911434548"/>-<xref ref-type="bibr" rid="bibr5-1066896911434548">5</xref></sup> Their clinical characteristics, along with this case, are summarized in <xref ref-type="table" rid="table2-1066896911434548">Table 2</xref>. These tumors are variable in size (2.7 to 6.8 cm), and in cases 2 to 5, they were well circumscribed (not described in case 1). They also share morphological features similar to their cerebellar counterpart and a common IHC profile (reactivity to S100, α-inhibin, and neuron-specific enolase; negative results for HMB-45, Melan-A, and epithelial markers such as cytokeratin and epithelial membrane antigen). Curiously, CD56 stain was negative in both case 4 and our case, and it is said to be consistently immunoreactive in cerebellar hemangioblastomas.<sup><xref ref-type="bibr" rid="bibr1-1066896911434548">1</xref></sup></p>
<table-wrap id="table2-1066896911434548" position="float">
<label>Table 2.</label>
<caption><p>Cases of Sporadic Primary Renal Hemangioblastoma Reported</p></caption>
<graphic alternate-form-of="table2-1066896911434548" xlink:href="10.1177_1066896911434548-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Case No.</th>
<th align="center">Age (year)</th>
<th align="center">Gender</th>
<th align="center">Size (cm)</th>
<th align="center">Presence of VHL Disease</th>
<th align="center">Outcome</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>71</td>
<td>F</td>
<td>6.8</td>
<td>Not stated</td>
<td>ANED, 9 years</td>
<td>Nonaka et al<sup><xref ref-type="bibr" rid="bibr4-1066896911434548">4</xref></sup></td>
</tr>
<tr>
<td>2</td>
<td>58</td>
<td>M</td>
<td>5.5</td>
<td>No</td>
<td>ANED, 2 years</td>
<td>Ip et al<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref></sup></td>
</tr>
<tr>
<td>3</td>
<td>55</td>
<td>F</td>
<td>3.5</td>
<td>No</td>
<td>N/A</td>
<td>Ip et al<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref></sup></td>
</tr>
<tr>
<td>4</td>
<td>64</td>
<td>M</td>
<td>3.2</td>
<td>No</td>
<td>ANED, 1 year</td>
<td>Verine et al<sup><xref ref-type="bibr" rid="bibr5-1066896911434548">5</xref></sup></td>
</tr>
<tr>
<td>5</td>
<td>29</td>
<td>M</td>
<td>2.7</td>
<td>No</td>
<td>ANED, 20 months</td>
<td>Current case</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1066896911434548">
<p>Abbreviations: VHL, von Hippel-Lindau; ANED, alive without evidence of disease.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In contrast to the cases previously reported, our patient is much younger. This may raise the suspicion of VHL disease. According to the WHO Blue Book, the clinical diagnosis of VHL disease is based on the presence of hemangioblastoma in the CNS or retina, the presence of one of the typical VHL-associated tumors (clear-cell RCC, pheochromocytoma, epididymal cystadenoma, neuroendocrine tumors, etc), or a previous family history.<sup><xref ref-type="bibr" rid="bibr2-1066896911434548">2</xref></sup> This patient does not meet any of these criteria, and therefore, his case is considered sporadic. Compared with the age distribution of hemangioblastoma of the CNS, which peaks in the third to the fifth decade,<sup><xref ref-type="bibr" rid="bibr1-1066896911434548">1</xref></sup> the patients’ ages in previous reports seem to be higher (mean, 62 years old). The tendency to occur in older individuals was also noticed in soft-tissue and retroperitoneal hemangioblastomas.<sup><xref ref-type="bibr" rid="bibr6-1066896911434548">6</xref></sup> Further large-scale studies are necessary to elucidate whether there is an actual difference in age distribution between neural and extraneural cases.</p>
<p>Making the correct diagnosis of renal hemangioblastoma is challenging. RCC, which is far more common and possesses a wide morphological variation, is the most important differential diagnosis. The most common histological subtype, clear-cell RCC, shares main morphological characteristics with hemangioblastomas, such as clear cytoplasm and a vascular network.<sup><xref ref-type="bibr" rid="bibr1-1066896911434548">1</xref>,<xref ref-type="bibr" rid="bibr7-1066896911434548">7</xref>,<xref ref-type="bibr" rid="bibr8-1066896911434548">8</xref></sup> The presence of a pericytomatous growth pattern<sup><xref ref-type="bibr" rid="bibr5-1066896911434548">5</xref></sup> and intracytoplasmic lipid vacuoles<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref>,<xref ref-type="bibr" rid="bibr5-1066896911434548">5</xref></sup> are major clues to the diagnosis of hemangioblastoma. Other differential diagnoses include adrenal cortical carcinoma, epithelioid angiomyolipoma, and paraganglioma, which are also mimickers of RCC.<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref>,<xref ref-type="bibr" rid="bibr9-1066896911434548">9</xref></sup> An IHC panel is useful to differentiate these morphologically similar neoplasms, and their IHC profiles are summarized in <xref ref-type="table" rid="table3-1066896911434548">Table 3</xref>. Before the first report of renal hemangioblastoma,<sup><xref ref-type="bibr" rid="bibr4-1066896911434548">4</xref></sup> it is possible that more cases had been diagnosed as other morphologically similar tumors because of morphological similarity.</p>
<table-wrap id="table3-1066896911434548" position="float">
<label>Table 3.</label>
<caption><p>Immunohistochemical Profiles of Renal Hemangioblastoma and Morphologically Similar Neoplasms</p></caption>
<graphic alternate-form-of="table3-1066896911434548" xlink:href="10.1177_1066896911434548-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Diagnostic Entity and Reference</th>
<th align="center">S100</th>
<th align="center">α-Inhibin</th>
<th align="center">Melan-A</th>
<th align="center">Epithelial Markers<sup><xref ref-type="table-fn" rid="table-fn3-1066896911434548">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemangioblastoma<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref></sup></td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Clear-cell renal-cell carcinoma<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref>,<xref ref-type="bibr" rid="bibr9-1066896911434548">9</xref></sup></td>
<td>−</td>
<td>−</td>
<td>+/−</td>
<td>+</td>
</tr>
<tr>
<td>Epithelioid angiomyolipoma<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref>,<xref ref-type="bibr" rid="bibr8-1066896911434548">8</xref></sup></td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Adrenal cortical carcinoma<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref>,<xref ref-type="bibr" rid="bibr8-1066896911434548">8</xref>,<xref ref-type="bibr" rid="bibr9-1066896911434548">9</xref></sup></td>
<td>+/−</td>
<td>+</td>
<td>+</td>
<td>+/−</td>
</tr>
<tr>
<td>Paraganglioma<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref>,<xref ref-type="bibr" rid="bibr9-1066896911434548">9</xref></sup></td>
<td>+/−<sup><xref ref-type="table-fn" rid="table-fn4-1066896911434548">b</xref></sup></td>
<td>−</td>
<td>+/−</td>
<td>−</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1066896911434548">
<p>Abbreviations: +, positive; −, negative; +/−, variable.</p>
</fn>
<fn id="table-fn3-1066896911434548">
<label>a</label>
<p>Cytokeratin and epithelial membrane antigen.</p>
</fn>
<fn id="table-fn4-1066896911434548">
<label>b</label>
<p>Positive mainly in sustentacular cells.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In conclusion, hemangioblastoma of the kidney is a rare tumor with indolent clinical behavior. It occurs not only in middle-aged to elderly patients as described before<sup><xref ref-type="bibr" rid="bibr3-1066896911434548">3</xref><xref ref-type="bibr" rid="bibr4-1066896911434548"/>-<xref ref-type="bibr" rid="bibr5-1066896911434548">5</xref></sup> but also in a younger population. It mimics RCC in morphology and may lead to overdiagnosis and unnecessary treatment. Recognition of this entity and careful IHC investigation are keys to a correct pathological diagnosis.</p>
</sec>
</body>
<back>
<ack><p>We appreciate the kind advice in diagnosis by Prof Christopher D. M. Fletcher (Brigham and Women’s Hospital, Boston, MA, USA) and assistance in IHC staining (S100, HMB-45, and neuron-specific enolase) by Dr Yi-Chen Yeh (the Veterans General Hospital, Taipei, Taiwan).</p></ack>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1066896911434548">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Aldape</surname><given-names>KD</given-names></name>
<name><surname>Plate</surname><given-names>KH</given-names></name>
<name><surname>Vortmeyer</surname><given-names>AO</given-names></name>
<name><surname>Zagzag</surname><given-names>D</given-names></name>
<name><surname>Neumann</surname><given-names>HPH</given-names></name>
</person-group>. <article-title>Haemangioblastoma</article-title>. In: <person-group person-group-type="editor">
<name><surname>Louis</surname><given-names>DN</given-names></name>
<name><surname>Ohgaki</surname><given-names>H</given-names></name>
<name><surname>Wiestler</surname><given-names>OD</given-names></name>
<name><surname>Cavenee</surname><given-names>WK</given-names></name>
</person-group>, eds. <source>WHO Classification of Tumours of the Central Nervous System</source>. <edition>4th ed.</edition> <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC Press</publisher-name>; <year>2007</year>:<fpage>184</fpage>-<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr2-1066896911434548">
<label>2.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Plate</surname><given-names>KH</given-names></name>
<name><surname>Vortmeyer</surname><given-names>AO</given-names></name>
<name><surname>Zagzag</surname><given-names>D</given-names></name>
<name><surname>Neumann</surname><given-names>HPH</given-names></name>
</person-group>. <article-title>Von Hippel-Lindau disease and haemangioblastoma</article-title>. In: <person-group person-group-type="editor">
<name><surname>Louis</surname><given-names>DN</given-names></name>
<name><surname>Ohgaki</surname><given-names>H</given-names></name>
<name><surname>Wiestler</surname><given-names>OD</given-names></name>
<name><surname>Cavenee</surname><given-names>WK</given-names></name>
</person-group>, eds. <source>WHO Classification of Tumours of the Central Nervous System</source>. <edition>4th ed.</edition> <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC Press</publisher-name>; <year>2007</year>:<fpage>215</fpage>-<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr3-1066896911434548">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ip</surname><given-names>YT</given-names></name>
<name><surname>Yuan</surname><given-names>JQ</given-names></name>
<name><surname>Cheung</surname><given-names>H</given-names></name>
<name><surname>Chan</surname><given-names>JK</given-names></name>
</person-group>. <article-title>Sporadic hemangioblastoma of the kidney: an underrecognized pseudomalignant tumor?</article-title> <source>Am J Surg Pathol</source>. <year>2010</year>;<volume>34</volume>:<fpage>1695</fpage>-<lpage>1700</lpage>.</citation>
</ref>
<ref id="bibr4-1066896911434548">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nonaka</surname><given-names>D</given-names></name>
<name><surname>Rodriguez</surname><given-names>J</given-names></name>
<name><surname>Rosai</surname><given-names>J</given-names></name>
</person-group>. <article-title>Extraneural hemangioblastoma: a report of 5 cases</article-title>. <source>Am J Surg Pathol</source>. <year>2007</year>;<volume>31</volume>:<fpage>1545</fpage>-<lpage>1551</lpage>.</citation>
</ref>
<ref id="bibr5-1066896911434548">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Verine</surname><given-names>J</given-names></name>
<name><surname>Sandid</surname><given-names>W</given-names></name>
<name><surname>Miquel</surname><given-names>C</given-names></name>
<name><surname>Vignaud</surname><given-names>J</given-names></name>
<name><surname>Mongiat-Artus</surname><given-names>P</given-names></name>
</person-group>. <article-title>Sporadic hemangioblastoma of the kidney: an underrecognized pseudomalignant tumor?</article-title> <source>Am J Surg Pathol</source>. <year>2011</year>;<volume>35</volume>:<fpage>623</fpage>-<lpage>624</lpage>.</citation>
</ref>
<ref id="bibr6-1066896911434548">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshida</surname><given-names>A</given-names></name>
<name><surname>Oda</surname><given-names>R</given-names></name>
<name><surname>Shibahara</surname><given-names>J</given-names></name>
<name><surname>Fukayama</surname><given-names>M</given-names></name>
<name><surname>Tsuda</surname><given-names>H</given-names></name>
</person-group>. <article-title>Soft-tissue hemangioblastoma of the retroperitoneum: a case study and review of the literature</article-title>. <source>Appl Immunohistochem Mol Morphol</source>. <year>2010</year>;<volume>18</volume>:<fpage>479</fpage>-<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr7-1066896911434548">
<label>7.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Grignon</surname><given-names>DJ</given-names></name>
<name><surname>Eble</surname><given-names>JN</given-names></name>
<name><surname>Bonsib</surname><given-names>SM</given-names></name>
<name><surname>Moch</surname><given-names>H</given-names></name>
</person-group>. <article-title>Clear cell renal cell carcinoma</article-title>. In: <person-group person-group-type="editor">
<name><surname>Eble</surname><given-names>JN</given-names></name>
<name><surname>Sauter</surname><given-names>G</given-names></name>
<name><surname>Epstein</surname><given-names>JI</given-names></name>
<name><surname>Sesterhenn</surname><given-names>IA</given-names></name>
</person-group>, eds. <source>World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs</source>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC Press</publisher-name>; <year>2004</year>:<fpage>23</fpage>-<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr8-1066896911434548">
<label>8.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Amin</surname><given-names>MB</given-names></name>
</person-group>, ed. <source>Diagnostic Pathology: Genitourinary</source>. <publisher-loc>Salt Lake City, UT</publisher-loc>: <publisher-name>Amirsys</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr9-1066896911434548">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lapinski</surname><given-names>JE</given-names></name>
<name><surname>Chen</surname><given-names>L</given-names></name>
<name><surname>Zhou</surname><given-names>M</given-names></name>
</person-group>. <article-title>Distinguishing clear cell renal cell carcinoma, retroperitoneal paraganglioma, and adrenal cortical lesions on limited biopsy material: utility of immunohistochemical markers</article-title>. <source>Appl Immunohistochem Mol Morphol</source>. <year>2010</year>;<volume>18</volume>:<fpage>414</fpage>-<lpage>421</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>